...
首页> 外文期刊>Gut: Journal of the British Society of Gastroenterology >Nottingham trial of faecal occult blood testing for colorectal cancer: A 20-year follow-up
【24h】

Nottingham trial of faecal occult blood testing for colorectal cancer: A 20-year follow-up

机译:诺丁汉粪便隐血试验对大肠癌的试验:20年随访

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Three large randomised trials have shown that screening for colorectal cancer (CRC) using the faecal occult blood test (FOBt) can reduce the mortality from this disease. The largest of these trials, conducted in Nottingham since 1981, randomised 152 850 individuals between the ages of 45 and 74 years to an intervention arm receiving biennial Haemoccult (FOB) test kit or to a control arm. In 2006, the National Bowel Cancer Screening Programme was launched in England using the FOBt, with the expectation that it will reduce CRC mortality. Aims: To compare the CRC mortality and incidence in the intervention arm with the control arm after long-term follow-up. Methods: The 152 850 randomised individuals were followed up through local health records and central flagging (Office for National Statistics). Results: At a median follow-up of 19.5 years there was a 13% reduction in CRC mortality (95% CI 3% to 22%) in the intervention arm despite an uptake at first invitation of approximately 57%. The CRC mortality reduction in those accepting the first screening test, adjusted for the rate of non-compliers, was 18%. There was no significant difference in mortality from causes other than CRC between the intervention and control arms. Despite removing 615 adenomas >10 mm in size from the intervention arm, there was no significant difference in CRC incidence between the two arms. Conclusions: Although the reduction in CRC mortality was sustained, further follow-up of the screened population has not shown a significant reduction in the CRC incidence. Moreover, despite the removal of many large adenomas there was no reduction in the incidence of invasive cancer which was independent of sex and site of the tumour.
机译:背景:三项大型随机试验表明,使用粪便潜血试验(FOBt)筛查大肠癌(CRC)可以降低该病的死亡率。自1981年以来在诺丁汉进行的这些试验中规模最大的试验,将152850名年龄在45至74岁之间的患者随机分配到接受两年一次验血(FOB)试剂盒的干预组或对照组。 2006年,使用FOBt在英国启动了国家肠癌筛查计划,期望该计划将降低CRC死亡率。目的:比较长期随访后干预组和对照组CRC的死亡率和发生率。方法:通过当地健康记录和中央标记(国家统计局)对152 850名随机个体进行随访。结果:在中位随访时间为19.5年的情况下,尽管首次邀请时摄取了约57%,但干预组的CRC死亡率降低了13%(95%CI为3%至22%)。接受首次筛查测试的患者经非适应症发生率调整后,CRC死亡率降低了18%。干预组和对照组之间,除CRC以外的其他原因引起的死亡率没有显着差异。尽管从干预组中去除了615个大于10 mm的腺瘤,但两组之间的CRC发生率没有显着差异。结论:尽管CRC死亡率持续降低,但对筛查人群的进一步随访并未显示CRC发生率显着降低。此外,尽管去除了许多大腺瘤,但浸润性癌的发生率却没有降低,而浸润性癌的发生与性别和肿瘤部位无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号